Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Long-term Study of JTE-052 (delgocitinib) Ointment in Atopic Dermatitis
jRCT2080223500Phase 3Completed
- Sponsor
- Japan Tobacco
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of delgocitinib in atopic dermatitis (AD), sponsored by Japan Tobacco. Primary endpoint: Long-term safety and tolerability of delgocitinib ointment 0.5%. Started Mar 2017; status: completed.
02
Drugs
delgocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2080223500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223500.